Sandoz Lines Up Higher-Strength Adalimumab In Europe

Filing For 100mg/ml Version Of Hyrimoz Biosimilar Rival To Humira Accepted By EMA

 
• By Dave Wallace

Sandoz is looking to enter the European market for high-concentration adalimumab after announcing EMA acceptance of its filing for a 100mg/ml version of its Hyrimoz biosimilar. Celltrion and Stada/Alvotech already have higher-strength rivals to Humira available in Europe.

Three Player Chess Board
Could Europe soon become a three-player market for 100mg/ml adalimumab biosimilars? • Source: Shutterstock

More from Biosimilars

More from Products